Reckitt Benckiser kicks off USD 10 billion infant nutrition business sale: Bloomberg

Bids for the business, whose biggest operations are in the US, are expected at the end of May, the people said.

Published On 2022-04-29 07:51 GMT   |   Update On 2022-04-29 07:51 GMT

New Delhi: Reckitt Benckiser Group Plc has begun a sale process for its infant nutrition business in what's set to be one of the British consumer goods firm's largest-ever disposals, people with knowledge of the matter said.The London-listed company, which sells brands including Enfamil formula, sent out marketing materials to potential buyers this month, the people said. Reckitt could seek...

Login or Register to read the full article

New Delhi: Reckitt Benckiser Group Plc has begun a sale process for its infant nutrition business in what's set to be one of the British consumer goods firm's largest-ever disposals, people with knowledge of the matter said.

The London-listed company, which sells brands including Enfamil formula, sent out marketing materials to potential buyers this month, the people said. Reckitt could seek as much as $10 billion for the unit, according to the people, who asked not to be identified because the information is private.
Bids for the business, whose biggest operations are in the US, are expected at the end of May, the people said. It could attract interest mostly from private equity firms, the people said.
A sale would complete a reversal of Reckitt's largest purchase, the $17 billion acquisition of Mead Johnson Nutrition Co. five years ago under former Chief Executive Officer Rakesh Kapoor. His successor, Laxman Narasimhan, sold the Chinese infant formula part of that business to local buyout firm Primavera Capital for $2.2 billion last year, exiting one of its largest markets.
The company said at the time that the remaining operations in North America and other parts of the world had about 5.4 billion pounds ($7.3 billion) of net assets.

Read also: Reckitt Benckiser rebrands itself as Reckitt



Tags:    
Article Source : Bloomberg

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News